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Abstract
Objective: Human epidermal growth factor receptor 2 (HER-2), as a crucial factor involved in about 20% of breast cancer 
cases, is one of the most reliable tumor markers to determine prognosis and therapeutic trend of this disease. This marker 
is generally assessed by immunohistochemistry (IHC) technique. In the cases that result of IHC test cast doubt (+2), the test 
should be repeated or validated by applying in situ hybridization techniques, like chromogenic in situ hybridization (CISH). In 
this regard, the goal of current study was to figure out the link between different clinicopathological characteristics of patients 
suffering from invasive breast cancer, using tumor markers, hormone receptor (HR) and HER-2. Comparing IHC and CISH 
techniques for evaluating diagnostic value and usefulness of HER-2 were also the other objective of this study.
Materials and Methods: Based on this retrospective study, histological markers of 113 individuals suffering from invasive 
breast cancer -such as estrogen receptor (ER), progesterone receptor, HER-2 receptor, E-cadherin, CK5/6, vimentin and 
Ki67 were examined by IHC technique. HER-2 amplification of all patients was also evaluated by CISH. Clinicopathological 
information of the patients was also extracted from medical documents and their associations with tumor markers were 
statistically evaluated.               
Results: There is a significant relationship between tumor size, CK5/6 and tumor grade with HR status. Similar relationship 
was observed between HER-2 status and HR status, as well as vascular invasion (P<0.05). The comparison of HER-2 
amplification showed no complete concordance of the result obtained from these two techniques, with score +3.                
Conclusion: Since the status of HER-2 is very important in decision making of the treatment process, CISH technique is 
recommended in the malignant conditions as the primary test, instead of IHC. In this study, we also determined that HER-2 
expression is greatly correlated with ER- and PR- status. This might propose a better prognosis for HER-2+ patients. 
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Introduction
Breast carcinoma is a multifactorial ailment comprised of 
noticeable biological subtypes with vast variation in clinical, 
pathological and molecular features having various prognostic 
and therapeutic implications. The nature of this malignancy is 
interconnected with its clinical outcomes (1). It is important 
to note that up to 21 distinct histological subtypes and at least 
four various molecular subtypes of breast cancer, correlating 
with distinct risk factors, have thus far been diagnosed which 
are biologically different in presentations and results (2, 3). 
Evaluating different biological markers -including presence 
or absence of hormone (i.e. estrogen or progesterone) 
receptors (named respectively HR+ or HR-) and excessive 
level of human epidermal growth factor receptor 2 (HER-
2)- is the most applicable method for identifying the subtype 
of the cancer (4), leading to classification of some distinct 
subtypes of breast cancer: luminal A (HR+/HER-2-), triple 
negative (HR-/HER-2-), luminal B (HR+/HER-2+) and HER-
2-enriched (HR-/HER-2+) tumors (5).
HER-2 gene product is a 185-kDa trans-membrane growth 
factor receptor with tyrosine kinase activity involved in 
cellular signaling. It is responsible for regulating cell growth 
and development (6). Clinical studies show that HER-2 gene 
is amplified in 20-30% of all breast cancers (7), out of which 
overexpression is the direct result of this gene amplification 
in ~90-95% of cases (6). This phenomenon is a remarkable 
prognosis factor associated with lymph node metastasis, 
HR- tumors, high-grade tumor, great recurrence risk after 
operation, weak response to common chemotherapy and no 
chance of long-term survival (8).
HER-2 expression is an important factor in therapeutic 
decision-making of breast cancer, since HER-2 protein (HER-
2 gene product) is targeted for specific treatment by humanized 
recombinant monoclonal antibody Trastuzumab. So that, this 
drug could only be applied for treatment of patients with 
HER-2+ malignancy (9). 
These days, expression of estrogen receptor (ER), 
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progesterone receptor (PR) and HER-2 are measured by 
immunohistochemistry (IHC) technique, as a prognostic 
factor applied in the routine protocol of breast cancer 
treatment. In this technique, amplification of HER-2 is 
reported in three scores: i. No amplification of the targeted 
gene which is considered as +1, ii. An interface that does 
not indicate whether there is any increase in the HER-2 
protein level and it is shown as +2, in addition to iii. The 
definite amplification of HER-2 which is considered as +3. 
The patient’s IHC scored +2 should be rechecked by IHC 
or evaluated by some in situ hybridization techniques, like 
fluorescent in situ hybridization (FISH) or chromogenic in 
situ hybridization (CISH). Some studies implicate that CISH 
is more sensitive than IHC (10).
In this study, we examined sensitivity of the results 
obtained from IHC and CISH tests. For this purpose, HR 
(ER and PR) and HER-2 proteins of breast cancer patients 
were evaluated by these two techniques. In addition, all 
demographic and histopathological characteristics of the 
patients were recorded. The results of IHC test were scored 
as +1, +2 and +3, and compared to CISH test representing 
status of HER-2 expression (HER-2+ and HER-2- groups). 
Finally, histopathological characteristics and tumor subtypes 
obtaining from these two techniques were analyzed to detect 
meaningful correlations.  
Materials and Methods
This retrospective study was conducted over a period of 
four years at Mehr Hospital Pathology Department (Tehran, 
Iran). Over this time, 113 mastectomy specimens were 
obtained. In all cases, clinical features and tumor studies, 
including ER, PR, E-cadherin, CK5/6, vimentin and Ki67, as 
well as HER-2, were performed on formalin-fixed paraffin-
embedded (FFPE) tissue samples. Disease of specimens was 
completely gross based on a standard protocol. In addition, 
other data including tumor size, side of the breast, invasive 
ductal or lobular carcinoma, in situ component, grade and 
tumor vascular invasion were recorded.  
Tissue was subjected to routine processing and sections 
were stained with hematoxylin and eosin stain (11). The 
histopathological criteria were diagnosed based on WHO 
classification and the samples were graded, applying Modified 
Blooms Richardson Grading System. In addition, antibodies 
were applied to ER, PR, HER-2 receptor, E-cadherin, CK5/6, 
vimentin and Ki67.
Evaluation of progesterone receptor, estrogen receptor 
and HER-2 using IHC
Slices were made in thicknesses of 3-4 micrometers and 
placed on polyethylene lysine-coated slides. They were next 
deparaffined in xylene followed by distilling off with ethanol. 
Paraffin and healing slices were next set in 3% hydrogen 
peroxide solution (Sigma-Aldrich, USA). Antigenic reagents 
were performed by a 0.01 M citrate buffer solution with 
pH=6 for 20 minutes in microwave. In the next step, the 
sections were separately incubated with 7 antibodies (all 
from AbCam, UK) for 60 minutes at 37˚C: Monoclonal 
Mouse Anti-ErbB2 Affibody® Molecule, Monoclonal 
Mouse Antihuman Estrogen, Monoclonal Mouse Antihuman 
Progesterone, Monoclonal Mouse Anti-E Cadherin antibody, 
Monoclonal Mouse Anti-Cytokeratin 5+6 antibody (D5/16 
B4), Monoclonal Mouse Anti-vimentin antibody and 
Monoclonal Mouse Anti-Ki67 antibody. Normal tissue 
surrounding the tumor was used as the control of HER-
2, ER and PR. We could also quantify ER, PR staining by 
utilizing Allred score. All the slides were quantified by giving 
proportional scores regarding the percentage of cells, nuclear 
stain presence and intensity score considering the intensity 
of staining. The proportional score (PS) is as follows: 1% of 
cells representing nuclear stain, 10% of cells demonstrating 
nuclear stain, 33% of cells showing nuclear stain, 66% of 
cells expressing nuclear stain, 100% of cells showing nuclear 
stain. Intensity score (IS) is as follows: 0-negative weak 
staining, 1- intermediate staining and 2- strong staining. Total 
score (TS) is considered as follow: sum of PS+intensity. TS 
greater than 2 is regarded positive for significant expression 
of ER and PR. Immunohistochemical assessment of HER-
2 overexpression was considered positive, considering more 
than 10% of cells is severely stained (+3 score). In ambiguous 
cases (+2 score), they had to be confirmed by CISH.
Chromogenic in situ hybridization
In this experiment, paraffin blocks were divided into 5-6 
micron sections (at least 2 sections) to evaluate expression of 
HER-2 marker. We also categorized all original breast tumor 
tissues with either modified radical mastectomy or breast-
conserving surgery to confirm diagnosis of the invasive 
carcinomas.
The test has been conducted by applying CISH, based 
on Zyto Dot: 2C SPEC HER-2/CEN-17 dual Probes Kit 
protocol (Zytovision, Germany). The PD-12 probe contains 
digoxigenin-labeled polynucleotides targeting sequences of 
the HER-2 gene and DNA-labeled polynucleotides targeting 
alpha-satellites of the centromere of chromosome 17 causing 
formation of green and red signals, illustrated by light 
microscopy (×40 objective lens). All of these reactions were 
performed in two days, following four steps, in line with the 
kit protocol (www.zytovision.com).
CISH hybridization signal of one single copy of HER-2 
gene, appears like a distinct dark green dot-shaped signal, 
while the signal of one single copy of chromosome 17 
centromeric region appears as a distinct bright red dot-
shaped signal which can clearly be distinguished from the 
background counterstained with hematoxylin (Fig.1). All 
slides were analyzed and the results were recorded and scored 
in accordance to the American Society of Clinical Oncology/
College of American Pathologists (ASCO/CAP) guidelines. 
Briefly, the numbers of CEN-17 and HER-2 signals were 
counted in 100 non-overlapping invasive cancer cell nuclei, 
applying at least three distinct tumor fields (when possible). 
HER-2 signal heterogeneity was not regarded in this study. 
Where the mean HER-2/CEN-17 ratio in any field is 2 or 
greater, the tumor is, therefore, amplified. Where the ratio is 
less than 2 whereas average of HER-2 signal number per cell 
is equal to or less than 2, it is not amplified. Cases with a 
ratio of less than 2 and HER-2 signal number per cell between 
4 and 6 were considered as equivocal borderline results and 
after counting an additional 20 nuclei according to new 
ASCO/CAP guideline 2018 version (12, 13), final decision 
on the degree of amplification was made. 
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Fig.1: Illustration of a CISH result performed on the patient tumor sample. 
A. HER-2+ sample, whereby green-to-red ratio is more than 2 and B. 
HER-2- sample, whereby green-to-red ratio is less than 2 (red color is the 
indicator of chromosome 17 centromeric probes, and green color is the 
indicator of specified probes of HER-2 gene) (scale bar: 100 µm).
Ethical considerations
All experiments were performed in accordance with 
relevant guidelines and regulations. All FFPE samples were 
obtained from the Mehr Hospital. This study was approved 
by the Ethics Committee of Tarbiat Modares University 
(registered number: 52D/4922), Tehran, Iran. Written 
informed consent was obtained from each participant before 
FFPE sample collection.
Statistical analysis
In this study, chi-square data analysis and Fisher’s exact test 
were applied. All statistical analyses were conducted using 
Statistics Package for Social Sciences (SPSS) version 18 at 
the significant level of P<0.05. Quantitative variables were 
reported as mean ± SD and qualitative variables were also 
reported as frequency (%). 
Results
In the present study, various clinicopathological parameters 
in 113 cases of infiltrating ductal (102 cases) and lobular (11 
cases) carcinoma were analyzed and summarized in Table 1. 
The range of breast cancer patient age onset was between 27 
and 95 years old. Demographic data is given in Table 1.
The ER and PR relationship with pathological and 
demographic features, as well as clinical characteristics of 
patients are presented in Table 2.
Table 1: Demographic characteristics of ductal carcinoma breast cancer 
patients
Characteristics Number of subjects (%)
Age (Y)
   Mean 54.05 ± 12.729
   Range 27-95
Stage at diagnosis
   Stage I 37 (32.7)
   Stage II 28 (24.7)
   Stage III 27 (23.8)
Not determined 21 (18.5)
Breast involvement
   Right breast 67 (59.3)
   Left breast 42 (37.5)
   Bilateral involvement 4 (3.2)
Size of tumor
   More than 2 cm 81 (71)
   Less than 2 cm 32 (29)
Grade of tumor
   Grade 1 25 (22.1)
   Grade 2 57 (50.4)
   Grade 3 22 (19.4)
Not determined 9 (7.9)
Vascular invasion 57 (51.8)
Type of breast cancer
   Ductal carcinoma 101 (90.2)
   Lobular carcinoma 9 (8.0)
   In situ component of tumor 57 (50.9)
Hormone receptor status (IHC)
   ER+ 85 (75.9)
   ER- 27 (24.1)
   PR+ 69 (61.6)
   PR- 43 (38.4)
   ER- and PR- 30 (27)
HER-2
   +1 (negative) 27 (24.1)
   +2 (equivocal) 65 (58.0)
   +3 (positive) 21 (17.9)
Biomarkers
   E-cadherin positive 33 (68.8)
   CK5/6 positive 9 (14.1)
   Vimentin positive 4 (7.3)
   Ki67 92 (95.8)
HER-2 (CISH)
   Amplified 35 (31.3)
   Not amplified 77 (68.8)
   Triple negative 18 (16.1)
PR; Progesterone receptor and ER; Estrogen receptor.
A
B
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Table 2: Comparison of biomarker, demographic and clinical variables in terms of different combinations of ER and PR
Variable ER-/PR+ or ER+/PR- ER+/PR+ ER-/PR- P value (Chi-square test)
Age
≤45 7 (41.2) 17 (26.2) 5 (16.7) 0.18
>45 10 (58.8) 48 (73.8) 25 (83.3)
Tumor size
≤2 13 (76.5) 26 (40.0) 7 (23.3) 0.002
>2 4 (23.5) 39 (60.0) 23 (76.7)
Breast
Right 12 (70.6) 36 (55.4) 19 (63.3) 0.52
Left 4 (23.5) 28 (43.1) 10 (33.3)
Bilateral 1 (5.9) 1 (1.5) 1 (3.3)
Invasive ductal carcinoma
No 1 (5.9) 7 (10.8) 3 (10.0) 0.91
Yes 16 (94.1) 58 (89.2) 27 (90)
Invasive lobular carcinoma
No 17 (100.0) 58 (89.2) 28 (100.0) 0.38
Yes 0 (0.0) 7 (10.8) 0 (0.0)
In situ component
No 7 (41.2) 30 (46.2) 18 (60.0) 0.35
Yes 10 (58.8) 35 (53.8) 12 (40.0)
Grade
1 5 (31.3) 18 (28.6) 2 (8.0) 0.01
2 10 (62.5) 35 (55.6) 12 (48.0)
2 1 (6.3) 10 (15.9) 11 (44.0)
Vascular invasion
Negative 7 (41.2) 34 (52.3) 12 (42.9) 0.57
Positive 10 (58.8) 31 (47.7) 16 (57.1)
Stage
I 2 (66.7) 11 (55.0) 4 (44.4) 0.73
II 0 (0.0) 6 (30.0) 2 (22.2)
III 1 (33.3) 3 (15.0) 3 (33.3)
E-cadherin
Negative 3 (42.9) 10 (35.7) 2 (15.4) 0.38
Positive 4 (57.1) 18 (64.3) 11 (84.6)
CK5/6
Negative 1 (10.0) 2 (5.9) 14 (70.0) 0.04
Positive 9 (90.0) 32 (94.1) 6 (30.0)
Vimentin
Negative 6 (100.0) 33 (97.1) 12 (80) 0.11
Positive 0 (0.0) 1 (2.9) 3 (20.0)
Ki67
Negative 0 (0.0) 3 (5.3) 1 (4.0) 0.83
Positive 13 (100) 54 (94.7) 24 (96.0)
PR; Progesterone receptor and ER; Estrogen receptor. Data are presented as n (%).
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According to Table 2, only association of CK5/6 
with different combinations of ER and PR results 
is statistically noticeable (P<0.05). There is no 
significant association of E-cadherin, vimentin and 
Ki67 clinical variables with different combinations of 
ER and PR results (P>0.05). Chi-square analyses also 
indicate no significant association of tumor size and 
grade variables with different combinations of ER and 
PR (P<0.05). On the other hand, one of the goals of 
this study was to investigate potential association of 
HER-2 status (positive or negative result) using CISH 
technique with pathological and clinical variables of 
the patients. Results of this objective are reported in 
Tables 3 and 4. 
 Table 3: Comparison of histological variables in patients with positive and
negative CISH HER-2 result
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 Table 4: Comparison of demographic and clinical variables in patients
with positive and negative CISH HER-2 result
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Data are presented as n (%).
According to Table 4, results obtained from chi-square 
analysis revealed that only association of vascular invasion 
with CISH HER-2 status is statistically significant 
(P<0.05). Finally, in order to detect HER-2 amplification, 
sensitivity and specificity of CISH were compared to IHC 
technique. The results are illustrated in Figure 2.
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As shown in Figure 2, there are differences in HER-
2 amplification frequency of +2 and +3 scores between 
CISH and IHC methods. In the cases of +1 score (i.e. 
HER-2 negative) using IHC, the results were confirmed 
by CISH technique. But, in the cases of +2 and +3 scores 
using IHC (i.e. HER-2 positive), CISH technique reveals 
contradictory cases.
Fig.2: Comparison of two techniques, CISH and IHC, in HER-2 amplification 
detection.  HER2 status is defined according to IHC in 3 states: +1 (HER2 
negative) where the cell membranes are not stained or less than 10% of 
the cells are stained. +2 (Equivocal), in which the membrane contains more 
than 10% of the cells weakly or moderately stained and +3 (HER2 positive) 
in which the membrane of more than 10% of the cells is completely and 
severely stained.
Discussion
Breast cancer is the main cause of around 9-34% of all 
patient malignancies in women, and about 1 million new 
cases are recognized annually around the world (14). In 
addition, breast cancer is a widespread type of malignancy 
occurring in women living in developed countries and it is 
the fifth cause of death among all cancers (14, 15). One of 
the important issues in diagnosis and treatment of breast 
cancer is impossibility of early detection (16). Therefore, 
improving diagnostic process will have a remarkable 
output in the consequences of breast cancer. 
Prognostic and diagnostic factors play important role 
in several aspects, including perception of the disease 
process in patients, predicting disease outcome, choosing 
the right treatment and planning for implementation of the 
extra treatment process. ER and PR status determination 
is very important in choosing the right treatment of 
breast cancer (17). These receptors are also considered as 
prognostic factors during hormone therapy (18).
In our study, the onset age mean of patients is 54 which, 
to some extent, is higher than the patients in other studies. 
In a study performed by Erbil et al. (19) age mean of 
the total number of 231 patients was 45 years and in 
the other study carried out by Mohaghegh et al. (20), 
the reported average of age was 48.3 years. In a study 
conducted by Payandeh et al. (21), the age mean of 
patients was 46.39 years.
In our study, 85 (75.9%) of the total cases were ER+, 
while 69 (61.6%) of them were PR+. Therefore, in 
our population study, ER+ patients have considerable 
prevalence and in comparison with other studies, the 
number of ER+ individuals is greater than that of PR+ 
(22, 23).
There are controversial reports on association of HR 
with clinicopathological features of the patients. In our 
study, no significant association between ER and PR 
with pathological features of E-cadherin, vimentin and 
Ki67 was observed. Furthermore, although there was a 
correlation between tumor size and grade of the disease, 
in addition to CK5/6, we did not notice a remarkable 
link between HR status and clinical features as well as 
demographic information including age, stage of disease, 
invasive lobular and in situ component. Thike et al. (24) 
showed that there is no association between age and HR 
status. However, in another study performed by Jalava 
et al. (23) an association between age and ER status was 
determined. Jalava et al. (23) and Aaltomaa et al. (25) 
showed no specific relationship between tumor size and 
HR status. However, in this study, we determined that 
size of the tumor in HR+ patients was more than 2 cm. 
Moreover, Moreover, in a study a lack of correlation has 
been reported between HR and histological analysis of 
carcinoma cells, while in several studies a correlation 
between HR+ and invasive lobular cancer was reported. 
HR+ status is generally common in patients with low 
tumor stage according to the result obtained from our 
study. However, due to the lack of samples with diagnosed 
stage of disease, it was not statistically significant. Our 
results also indicate that HR+ tumors have more +2 score 
than HR- tumors. This indication is in line with several, 
but not all, studies (23). The basal type cytokeratin CK4/5 
expression correlates with poor prognostic features, such 
as early recurrence, axillary lymph node positivity, high 
tumor grade, Ki-67 positivity and ER negativity (25). Our 
results showed that CK4/5 is often seen in HR- samples, in 
accordance with those of Choccalingam et al. (26) reports 
who also demonstrated that basal-like breast cancer 
expression, defined by basal cytokeratin expression, 
correlates with negative hormonal status and shorter 
disease-free intervals. Trastuzumab drug is used to treat 
patients suffering from HER-2+ invasive breast cancer 
tumors. In HER-2- cases, however, administration of this 
drug not only fails to have any benefit for the patients, 
but also it results in cardiotoxicity and additional costs for 
patients (27). 
In the present study, 35 (31%) patients showed 
overexpression of HER-2. The worldwide prevalence of 
women with HER-2+ breast cancer is 15-20% of the total 
affected cases which is also related to invasive forms of 
the disease (12).  HER-2+ cancer cells can produce two 
millions copy of the relevant protein on their surfaces 
which is almost 100 fold more than normal cells. This 
 Cell J, Vol 21, No 3, October-December (Autumn) 2019 328
HER-2 Amplification and Breast Cancer Tumor Markers
promotes the cancer cells to grow and reproduce faster. An 
essential step in the signaling pathway leading to cancer 
cell growth is the dimerization of the HER-2 receptor 
protein (28). Several studies have reported the relationship 
between HER-2 and prognostic factors (29). In a research 
study, Konecny et al. (30) showed a reverse relationship 
of HER-2 with ER and PR status. Additionally, in a cohort 
study, a reverse correlation of HER-2 with HR status as 
well as a positive correlation between tumor grade and 
overexpression of HER-2 was reported (31).
In our study, most of the HER-2+ patients were aged 
more than 45 years old. According to our results, 
HER-2 showed a significant relationship with tumor 
vascular invasion; in most of the HER-2+ patients, 
tumor also had vascular invasion, while in the case 
of HER-2- patients, vascular invasion showed no 
statistical difference. Other prognostic factors related 
to breast cancer showed no statistical relationship with 
HER-2 status. In this study, HER-2 gene expression 
significantly associated with ER- and PR- status. This 
is similar to the study of Ariga et al. (32). It has been 
recommended that this association could reflect a better 
prognosis. However, the other studies revealed that 
ER+/HER-2+ status accompanied with a poorer survival 
rate than ER+/HER-2- status. Therefore, it sounds that 
HER-2 expression is a better predicator of response to 
hormonal therapy than ER status itself.
Whereas these results are in accordance with previous 
studies, more sample size and clinicopathological 
information is needed to reach more precise and 
comprehensive results. In this way, individuals who are 
candidates for HER-2 examination, in the process of 
treatment could be diagnosed at the early stage of disease 
using CISH technique, with no need of IHC technique 
application. 
In this study, we analyzed the frequency of patient sample 
features by IHC and CISH methods. As mentioned previously, 
the results of 18 (16.1%) patients, analyzed by IHC and CISH 
techniques, were triple negative and 30 (27%) patients were 
ER- and PR- synchronously. However, this finding contradict 
with the previously reported frequency of triple negative 
breast cancer patients 54.83% among infiltrating ductal 
carcinoma. In addition, Sandhu et al. (33) in another study 
reported 31% prevalence of triple negative breast cancer in 
7223 of Indian patients.
As mentioned before, we used CISH technique in our 
study. In HER-2 examination, one of the remarkable 
privileges of CISH over IHC is the increase of specificity 
and sensitivity. The other advantage of in situ hybridization 
method for HER-2 is that this examination be done 
through a comparative way with a reference sequence 
in one reaction on a slide which results in reduction of 
errors and increase of accuracy. Relatively qualitative 
method is another limitation of IHC technique, leading 
to inaccuracy of +1, +2 and +3 scores distinction related 
to HER-2. Moreover, this method is affected by technical 
errors, especially experience of operator (34).
In the case of solid tumors, CISH is better and the 
relative slides could be conserved longer, compared 
to FISH method. Additionally, detection of gene 
amplification is more beneficial using CISH in contrast 
to FISH, regarding that: i. In permanent staining, samples 
can be archived, ii. Bright field microscopy application 
would be feasible, iii. Identification of the target cells is 
easy, and iv. Tumor heterogeneity is easily assessed (35). 
In this study, we compared the results of CISH with IHC 
tests by examining a number of breast cancers.
Herceptin is an antibody-based drug utilized to treat 
breast cancer, by targeting overexpression of HER-2 
protein, as it is observed in about one-third of breast cancer 
patients. Therefore, Herceptin is prescribed for HER-2+ 
patients. On the other hand, prescribing this medication 
for patients who are not diagnosed with conclusive HER-
2 gene expression may lead to adverse side-effects and 
even faster disease progression as well as economically 
imposing high costs to the patients’ family and public 
health system. Usually, +1 score is considered as non-
amplification of HER-2 in IHC tests. 
Currently, IHC tests are performed on most patients 
with breast cancer referring to laboratories in order to 
test for ER, PR, E-cadherin, CK5/6, vimentin and Ki67, 
among which HER-2 gene amplification is examined 
to prescribe and use Herceptin. In IHC technique for 
HER-2 is classified to +1, +2, and +3 scores. While the 
+1 score is considered as HER-2 non-amplified class, 
the +3 score is considered as definitely amplified HER-
2. The +2 score is considered as equivocal, meaning that 
there is uncertainties in the HER-2 expression of patients. 
Therefore, either IHC tests should be repeated or the 
sample evaluation should be validated by FISH or CISH 
test (10), imposing more costs and time consequently. 
As previously mentioned, definitive answer to the HER-
2 status is crucial for making decision to prescribe 
Herceptin.
In this study, we also compared the results of HER-2 
amplifications by IHC and CISH techniques. According 
to results, CISH technique is considered more reliable 
than IHC. This comparisons show that only the cases 
with +1 score is considered non-amplified in IHC, fully 
validated by CISH method. Interestingly, the +2 score, 
which are considered equivocal results, account for 
58% (65 patients) of all cases. In other words, only less 
than half of the patients receive the ultimate result using 
this test and their results must be verified by repeating 
experiment or utilizing other techniques such as CISH or 
FISH. Therefore, despite cheaper cost of IHC technique, 
it seems that would be a more rational to perform CISH 
test in patients from the beginning. It is worthy to note 
that HER-2+ patients with +2 score results (74% of the 
cases) were verified through CISH method.
The results obtained from CISH test showed 2 patients, 
out of 20 HER-2+ cases with +3 IHC score, were 
actually HER-2-. False positivity of these 2 patients, 
as a significant IHC problem to test HER-2 protein 
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overexpression, might lead to wrong process of their 
disease treatment. A minority of cases of breast cancer 
scoring HER-2 (+3) by IHC using Herceptin test may 
not be associated with findings obtained from CISH, 
which confirms that the CISH technique has a higher 
accuracy and sensitivity (36).
In this project, we also calculated the rate of similarity 
between IHC and CISH results from two aspects: i. 
Proportion of the negative (+1) or positive (+3) cases 
obtained from IHC, to CISH and ii. Proportion of 
the cases identified as +2 IHC, to the CISH HER-2+. 
Considering all these results, the rate of similarity 
between IHC and CISH in the cases of +1 and +3 
scores was around 95.8% (45/47) and the concordance 
between +2 score and positive cases of CISH were 
around 26.2% (17/65). This result may be due to 
polysemy of chromosome 17 in breast tumors which 
may lead +2 IHC score of the cases to show false 
positive (37, 38). Totally, the overall concordance of 
these two techniques for detecting HER-2+ tumors is 
about 61%, while in the other studies, this concordance 
was varied from 52 to 82% (39). In other studies, the 
relationship between results of FISH/CISH techniques 
and IHC techniques has been reported. For instance, 
in a study performed by Bahreini et al. (40), it was 
demonstrated that 36% of +2 IHC score cases, 
identified by FISH technique, were positive and 64% 
were negative.
Conclusion
Since the results of HER-2 status is important for making 
decision of the treatment process, CISH technique is 
recommended to test HER-2 expression in the malignant 
and invasive conditions rather than IHC. Additionally, in 
the presented study, HER-2 expression was significantly 
linked to ER- and PR- status that may reflect a better 
prognosis.
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